About: Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles
Creator	Liu, Jie Chen, Man Gangopadhyay, Anu Zarnitsyn, Vladimir Corbett, Kizzmekia Graham, Barney Johnson, Teresa Kines, Rhonda Nicewonger, John Pang, Yuk-Ying Prausnitz, Mark Schiller, John
Source	PMC
abstract	Human papilloma virus-like particles (HPV VLP) serve as the basis of the current licensed vaccines for HPV. We have previously shown that encapsidation of DNA expressing the model antigen M/M2 from respiratory syncytial virus (RSV) in HPV pseudovirions (PsV) is immunogenic when delivered intravaginally. Because the HPV capsids confer tropism for basal epithelium, they represent attractive carriers for vaccination targeted to the skin using microneedles. In this study we asked: 1) whether HPV16 VLP administered by microneedles could induce protective immune responses to HPV16 and 2) whether HPV16 PsV-encapsidated plasmids delivered by microneedles could elicit immune responses to both HPV and the antigen delivered by the transgene. Mice immunized with HPV16 VLP coated microneedles generated robust neutralizing antibody responses and were protected from HPV16 challenge. Microneedle arrays coated with HPV16-M/M2 or HPV16-F protein (genes of RSV) were then tested and dose-dependent HPV and F-specific antibody responses were detected post-immunization, and M/M2-specific T-cell responses were detected post RSV challenge, respectively. HPV16 PsV-F immunized mice were fully protected from challenge with HPV16 PsV and had reduced RSV viral load in lung and nose upon intranasal RSV challenge. In summary, HPV16 PsV-encapsidated DNA delivered by microneedles induced neutralizing antibody responses against HPV and primed for antibody and T-cell responses to RSV antigens encoded by the encapsidated plasmids. Although the immunogenicity of the DNA component was just above the dose response threshold, the HPV-specific immunity was robust. Taken together, these data suggest microneedle delivery of lyophilized HPV PsV could provide a practical, thermostable combined vaccine approach that could be developed for clinical evaluation.
has issue date	2015-03-18(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0120797
bibo:pmid	25785935
has license	cc0
sha1sum (hex)	592c1efd20dcb1ff5644f5d20e76f2c28a2b8da0
schema:url	https://doi.org/10.1371/journal.pone.0120797
resource representing a document's title	Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles
has PubMed Central identifier	PMC4364728
has PubMed identifier	25785935
schema:publication	PLoS One
resource representing a document's body	covid:592c1efd20dcb1ff5644f5d20e76f2c28a2b8da0#body_text
is schema:about of	named entity 'PsV' named entity 'HPV16' named entity 'combined' named entity 'responses' named entity 'delivered' named entity 'serve' named entity 'neutralizing antibody' named entity 'antigen' named entity 'Vaccination' covid:arg/592c1efd20dcb1ff5644f5d20e76f2c28a2b8da0 named entity 'vaccination' named entity 'delivered' named entity 'tropism' named entity 'delivered' named entity 'papilloma' named entity 'encoded' named entity 'PsV' named entity 'DNA' named entity 'targeted' named entity 'DNA' named entity 'protein' named entity 'RSV' named entity 'RSV' named entity 'encapsidated' named entity 'lung' named entity 'RSV' named entity 'antibody' named entity 'HPV16' named entity 'respiratory syncytial virus' named entity 'PsV' named entity 'PsV' named entity 'VLP' named entity 'immunization' named entity 'RSV' named entity 'antigens' named entity 'HPV16' named entity 'HPV' named entity 'vaccine' named entity 'antigen' named entity 'HPV16' named entity 'immunogenic' named entity 'T-cell' named entity 'immune responses' named entity 'encapsidation' named entity 'protein' named entity 'capsids' named entity 'viral load' named entity 'plasmids' named entity 'specific immunity' named entity 'Encapsidated' named entity 'coated' named entity 'generated' named entity 'HPV' named entity 'San Diego' named entity 'distilled water' named entity 'HPV16' named entity 'HPV16' named entity 'HPV16' named entity 'infection' named entity 'mice' named entity 'T-cell' named entity 'M/M2' named entity 'PsV' named entity 'mice' named entity 'serotype' named entity 'HPV vaccination' named entity 'animal work' named entity 'dip coating' named entity 'flow cytometry' named entity 'CD4 +'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software